DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
drugmaker Sandoz - 2 We've - 1 it'll - 1 Prem Shah - 1 drugmaker - 1 Amgen's Amjevita - 1 Murdo Gordon - 1 Abbvie - 1
Top related locs:
U.S Red California Rotkreuz Switzerland KS United States
Top related orgs:
Sandoz - 2 Novartis - 2 CVS Health - 1 CVS - 1 Cardinal Health - 1 Novartis Pharmaceuticals - 1 FDA - 1 Blue - 1

Search resuls for: "drugmaker Sandoz"


2 mentions found


☆ CVS pushes into making cheaper versions of complex drugs with new discount Humira
  + stars: | 2023-08-23 | by ( Bertha Coombs | ) www.cnbc.com   time to read: +4 min
CVS Health is partnering with drugmaker Sandoz to produce a near identical version of the blockbuster arthritis treatment Humira that will sell for 80% below the price of the brand-named drug. The move is part of the company's new venture focused on securing, and in some cases co-producing, biosimilar drugs, which are the equivalent of generic versions of complex gene or protein-based therapies known as biologics. CVS is already one of the leading players when it comes to sourcing generic drugs through Red Oak, its joint venture with Cardinal Health . Abbvie reported more than $4 billion in Humira sales in its most recent quarter, which was slightly better than expected. Correction: CVS Health subsidiary Cordavis will partner with Sandoz on biosimilar drugs.
Persons: drugmaker Sandoz, We've, it'll, Prem Shah, drugmaker, Amgen's Amjevita, Murdo Gordon, Abbvie, Cuban's, John Ransom, Raymond James, Ransom, Sandoz Organizations: CVS Health, CVS, Cardinal Health, Novartis Pharmaceuticals, Sandoz, Novartis, FDA, Blue, Drug Company, Amazon Pharmacy Locations: U.S, Red, California
☆ Sandoz launches rival version of AbbVie's arthritis drug Humira
  + stars: | 2023-07-01 | by ( ) www.reuters.com   time to read: +2 min
[1/2] The logo of Swiss drugmaker Novartis and its divisions Sandoz and Alcon are seen at an office building in Rotkreuz, Switzerland, January 29, 2020. REUTERS/Arnd Wiegmann/Fle PhotoJuly 1 (Reuters) - Swiss drugmaker Sandoz said on Saturday it had launched a biosimilar version of AbbVie Inc's (ABBV.N) big selling arthritis treatment Humira, adding to U.S. competition for the drug that started in January. The Novartis (NOVN.S)-owned company said its drug, Hyrimoz, will be priced at a 5% discount off Humira’s current list price of $6,922 per month, but that it was also offering an unbranded version of Humira at an 81% discount. The lower-priced version may attract healthcare systems that act as both an insurer and a provider and typically do not seek after-market discounts, as pharmacy benefit managers do. Rival Amgen Inc (AMGN.O) was the first to launch a biosimilar of Humira earlier this year, which debuted at a 5% and 55% discount to Humira, depending on who was purchasing.
Persons: Arnd, drugmaker Sandoz, drugmakers, Patrick Wingrove, Edwina Gibbs Organizations: Swiss, Novartis, Sandoz, REUTERS, Amgen, Pfizer Inc, Thomson Locations: Rotkreuz, Switzerland, KS, United States
0 next >>
Total: 2